Your Browser Is No Longer Supported. Please upgrade your browser from Internet Explorer 10 to Internet Explorer 11 or higher
We write to you as leading participants in the prescription drug supply chain – i.e., manufacturers, distributors, payers, physicians, pharmacies, testing laboratories, treatment providers – as
Along with other organizations, SHM signs onto a letter to CMS supporting antibiotic stewardship requirements for long term care facilities (LTCFs) in order to participate in Medicare programs.
SHM submitted comments regarding the pain management questions in the HCAHPS survey to Medicare in the Outpatient Prospective Payment System (OPPS) proposed rule.
SHM urges Congress to take action to address the opioid crisis facing the United States.
SHM sent a support letter to Reps. Blumenauer and Mullin for their legislation, the Overdose Prevention and Patient Safety Act.
The Mainstreaming Addiction Treatment Act (S. 2074) is the companion bill to H.R. 2482. This bill will increase access to buprenorphine, a lifesaving addiction treatment, by eliminating the "X
SHM responds to the House Energy and Commerce Republicans' request for information regarding opioid and substance use disorder treatment. This letter focuses specifically on the need to deregulate
SHM joined a multi-stakeholder letter urging the Acting Secretary of Health and Human Services (HHS) to finalize guidelines that would expand access to buprenorphine.
SHM joined a multi-stakeholder letter urging Congress to expand access to buprenorphine. The letter urged Congress to include legislation to address the opioid epidemic in the upcoming COVID
SHM joined nearly 200 organizations urging Congress to pass the Mainstreaming Addiction Treatment Act before the end of the 117th Congressional session.